bola viruses (EBOVs), together with Marburgvirus, are a highly diverse group of viruses that constitute the Filoviridae. Almost all of them, including the strain responsible for the latest outbreak in West Africa, cause a highly lethal, rapidly progressing hemorrhagic fever in humans and nonhuman primates (1, 2) . However, there is currently no licensed drug treatment or broadly active vaccine (3), making them important public health threats and potential biothreat agents. Because, like most viruses, EBOV depends on host cell factors to complete its life cycle (4) , blocking such interactions may have a large impact on infection and disease outcome. Recent successes in cell culture and some animal models suggest that this approach holds promise for rapidly bringing new drugs to the clinic (5) .
EBOV binds to several types of cell surface proteins to initiate host cell entry (6) (7) (8) , after which it is internalized by macropinocytosis and follows an endosomal route to reach acidic compartments (9, 10). There, host proteases such as cathepsins cleave the viral glycoproteins (GPs) (11) , which bind to the endosomal membrane protein, NPC1, and eventually facilitate the release of the viral core to the cell cytoplasm, where replication begins (12, 13) . Previously, we showed that host calcium signaling proteins were important for EBOV host cell entry but were unable to identify the functional mechanism nor address whether they could be therapeutic targets (14) .
To identify and characterize upstream effectors regulating calcium signaling in the context of EBOV infection, we tested the importance of calcium channels using antagonists for each of the four common channel types (Fig. 1, A to  C, and fig. S1 ). Only compounds blocking L-type channels inhibited EBOV infection in HeLa cells, which is consistent with previous reports (15, 16) . Verapamil, a drug approved by the U.S. Food and Drug Administration (FDA) to treat cardiovascular diseases, efficiently inhibited EBOV infection with a half-maximal inhibitory concentration (IC 50 ) of 4 mM (Fig. 1A) . Similarly, two other structurally distinct L-type channel antagonists, nimodipine and diltiazem, also reduced EBOV infection efficiency ( fig. S1, A and B) . Tetrandrine, originally isolated from Chinese and Japanese herbs but now produced synthetically, was especially potent, with an IC 50 of 55 nM (Fig. 1B) . By contrast, gabapentin, representing a fifth distinct class of L-type channel inhibitor, had no effect, even at high concentrations (Fig.  1C ). This finding suggested that classical L-type channels were not the upstream factor in EBOV calcium-channel dependence. Recently, verapamil, nimodipine, and diltiazem were shown to also inhibit calcium signaling triggered by nicotinic acid adenine dinucleotide phosphate (NAADP) (17) . NAADP is a highly potent intracellular calciummobilizing agent and stimulates intracellular calcium channels to release Ca 2+ from endosomes and lysosomes (18) . This pathway is specifically blocked by the small-molecule antagonist Ned19 (19) . We found that Ned19 also blocked EBOV infection (Fig. 1D) TPC2 or TPC1 in the presence of gabapentin (100 mM), Ned19 (200 mM), or tetrandrine (500 nM), normalized to those before drug application. *P < 0.001 using analysis of variance, compared to current in the presence of gabapentin for TPC2 or without inhibitors for TPC1. Data are the mean T SEM.
no cytotoxicity at the highest concentration used ( fig. S2 ). Like verapamil and Ned19, tetrandrine was also a potent inhibitor of NAADP-stimulated calcium release (Fig. 1E and fig. S3 ). These results suggested a role for NAADP-stimulated calcium channels in EBOV infection and that tetrandrine could block this host factor. NAADP has been suggested to regulate endosome maturation through vesicular fusion and trafficking (20) . This would suggest a role in virus entry into cells, which was tested with pseudotyped viruses. Infection of cells by recombinant vesicular stomatitis virus bearing the glycoprotein of EBOV (rVSV-EBOV-GP) was highly sensitive to tetrandrine, verapamil, or Ned19 (Fig. 1F and  fig. S4A ). This suggests that NAADP-stimulated channel activity specifically affects the GP-mediated entry step of EBOV. Moreover, tetrandrine and verapamil potently inhibited infection of recombinant VSV bearing Marburgvirus glycoprotein, but inhibited infection only weakly for VSV, Lassa virus, Venezuelan equine encephalitis virus, or Rabies virus (Fig. 1F and fig. S4 , B and C), suggesting that filoviruses are much more dependent on this pathway than are other virus types.
To gain further insight into the connection between the NAADP-mediated pathway and EBOV infection, we sought to identify the effector calcium channel required for the infection. Recent studies have shown that two-pore channels (TPCs) are the major calcium channels activated by NAADP (21) . They are also activated by the phosphatidylinositol 3,5-bisphosphate [PI(3,5)P 2 ] and are highly conserved proteins with both TPC1 and TPC2 present in humans, mice, and other animals (22) . We found that mouse embryonic fibroblasts (MEFs) lacking TPC1 or TPC2 expression (Tpcn1 −/− or Tpcn2
) resisted EBOV infection ( Fig. 2A) . Overexpression of human TPCs in the mutant cells significantly recovered the infectivity ( fig. S5 ), suggesting the specific effects of gene knockout. Similarly, even though suppression of TPC expression by small interfering RNAs (siRNAs) was incomplete ( fig. S6) , EBOV infection was reduced in HeLa cells transfected with either TPC1 or TPC2 siRNAs (Fig. 2B) . In addition, overexpression of a dominant-negative form of TPC2, which was reported to efficiently block NAADP-stimulated calcium release (23), inhibited EBOV infection (Fig. 2C) . Furthermore, Ebola viruslike particles (VLPs) incubated with cells localized to TPC1-and TPC2-positive endosomal compartments (Fig. 2D) . Whole endolysosomal patchclamp analyses showed that tetrandrine blocked both TPC1-and TPC2-mediated current elicited by PI(3,5)P 2 as well as NAADP (Fig. 2, E and F,  and fig. S7 ). In contrast, gabapentin, which did not inhibit virus infection, had no effect on TPC2 function. Together, our data showed that TPCs, the effector channels of NAADP and PI(3,5)P 2 -mediated signaling, are important for EBOV infection, probably while virus is inside endosomes. Calcium channel inhibitors targeted TPCs, with tetrandrine being the most potent.
During host cell entry, EBOV is transported to acidic endosomes, which express lysosomalassociated membrane protein 1 (LAMP1) (9) . We found that VLPs still localized to LAMP1-positive vesicles in Tpcn1 −/− and Tpcn2 −/− MEFs, as well as inhibitor-treated cells ( fig. S8 ), indicating that this step was unaffected. The EBOV GP is then cleaved by endosomal cysteine proteases before virus-endosome membrane fusion can occur (11), and so we next examined whether precleaved GPs could overcome the action of the inhibitory drugs using rVSV-EBOV-GP pretreated with the protease thermolysin. Treatment with Ned19, tetrandrine, or verapamil still efficiently blocked precleaved virus infection, but a control cysteine protease inhibitor, E-64-D, did not ( fig. S9 ), indicating that the calcium channel inhibitors affect a late entry step after GP proteolysis in endosomes. When membrane fusion was evaluated, with a virus contents release assay (24), these inhibitors significantly reduced the contents mixing signal (Fig. 3A  and fig. S10 ), indicating that virus-endosome membrane fusion and virus capsid release into the cell cytoplasm were arrested. A recent study showed that blocking TPC2 function resulted in accumulation of epidermal growth factor (EGF) in LAMP1-positive endosomal compartments, suggesting a block of endosomal trafficking in these acidic compartments (25) . We found that tetrandrine-treated HeLa cells showed a similar accumulation of EGF, as well as Tpcn2 −/− MEFs, whereas Tpcn1 −/− MEFs showed less EGF accumulation (Fig. 3, B and C) . Moreover, Ebola VLPs and EGF colocalized in tetrandrinetreated cells (Fig. 3D) , suggesting that both use or converge upon a common endosomal trafficking route that is regulated by TPCs. Previously, EBOV entry was shown to be dependent on another endosomal protein, NPC1 (12, 13) . The small molecule U18666A induces a phenotype that mimics NPC1 deficiency, leading to cholesterol accumulation in endosomes. When cells were treated with U18666A, the pattern of EGF accumulation was similar to that seen after treatment with tetrandrine (Fig. 3C) . Moreover, treatment of rVSV-EBOV-GP-infected cells with verapamil or U18666A revealed similar inhibitory kinetics, with each becoming ineffective when the drug was added 1.5 to 2 hours after infection ( fig. S11 ), suggesting that each affected virus infection close to the same time. To further study this relationship and characterize the infection step affected by TPCs, we investigated viral colocalization with NPC1 or TPC2 (Fig. 3E) . In untreated cells, VLPs were found in compartments containing both NPC1 and TPC2, as well as a distinct compartment containing only TPC2. However, treatment with tetrandrine significantly (and with other channel inhibitors less potently) increased accumulation of VLPs in the TPC2(+)/NPC1(+) compartment while proportionately decreasing TPC2(+)/NPC1(-) compartment colocalization (Fig. 3F) . These results suggest that disrupting endosomal trafficking with tetrandrine potently alters viral distribution such that VLPs are retained in the NPC1(+) compartment. Because decreased colocalization with the TPC2 (+)/NPC1(-) compartment correlated with reduced infectivity, EBOV likely uses this compartment to enter host cells. Treatment with U18666A again resulted in VLP localization similar to that seen with calcium channel inhibitors (Fig. 3F ). This may be explained by a recent report showing that U18666A treatment caused endosomal calcium depletion. Moreover, cells carrying a defective NPC1 were shown to have a loss of NAADP response, suggesting a close association of TPCs and NPC1 in host cells, which may affect EBOV infection (26) . Finally, we addressed whether TPC function could be targeted for anti-EBOV therapy. First, primary macrophages, an initial target of virus infection in humans and other animals, were evaluated. Similar to its effect in HeLa cells, tetrandrine potently blocked EBOV infection in human monocyte-derived macrophages, with verapamil and Ned19 being effective but requiring high doses (Fig. 4A and fig. S12 ) that did not show cytotoxicity. Of these, tetrandrine was the best candidate for animal testing because of its high potency and low cytotoxicity in culture. Moreover, the dose of tetrandrine needed to inhibit virus infection (IC 50 = 55 nM) was at least a factor of 40 less than safe plasma concentrations achieved in mice and was reported to have good pharmacological properties, being well tolerated and having a long circulatory time (27) . We therefore assessed therapeutic efficacy in the mouse model of EBOV disease (28) . Mice were challenged with mouse-adapted EBOV and then given tetrandrine or saline every 2 days for 1 week. Starting tetrandrine treatment soon after infection significantly enhanced the survival of mice without any detectable side effects (Fig. 4B) . Clinical scores in treated mice remained low compared to the control group (Fig. 4, C and D, and  fig. S13 ). Virus titers in sera measured at day 3 after inoculation showed a factor of 1000 decrease (Fig. 4E) , and by day 9 virus was undetectable. Furthermore, when the treatment was started 1 day after virus challenge, half the mice survived (Fig. 4F) . These results indicate that tetrandrine is highly effective against disease in mice.
Taken together, we identified a role for TPCs in EBOV infection. These calcium channels appear responsible for controlling movement of endosomes containing virus particles. By disrupting TPC function, we prevented EBOV from escaping the endosomal network into the cell cytoplasm, halting infection. TPCs proved effective targets for existing drugs, with the bisbenzylisoquinoline alkaloid, tetrandrine, being the most potent. This may be due to its ability to block both TPC1 and TPC2, which regulate different stages of endosomal trafficking (22) . Tetrandrine is one representative from this drug class; other members are found in plants around the world (29) and may also block EBOV infection. Because the entry of Marburgvirus, a distantly related filovirus, was also affected, it is likely that all filoviruses require TPC function to infect cells and that tetrandrine is a broadspectrum filovirus inhibitor.
